Curtin University and Australian Red Cross Lifeblood Partner to Develop Innovative Faecal Transplant Pills for Clinical Trials

 

Curtin University and the Australian Red Cross Lifeblood are embarking on an innovative collaboration to develop a new fecal microbiota transplantation (FMT) capsule for clinical trials in Australia. This groundbreaking project aims to create a more accessible and patient-friendly method of administering FMT, which traditionally involves the transfer of fecal matter from a donor to a recipient to restore a healthy balance of gut microbiota.

The new FMT capsule will be administered orally and is designed to be more convenient and less invasive compared to traditional fecal transplant methods. The project combines Curtin University’s expertise in biotechnology and pharmaceutical sciences with the Australian Red Cross Lifeblood’s extensive experience in blood and tissue services. This partnership aims to address some of the challenges associated with current FMT procedures, such as the need for invasive delivery methods and the complexity of handling and processing fecal material.

Dr. Hani Al-Salami, Senior Lecturer at Curtin medical school in perth, Western Australia talks with The Wire’s Vanessa Gatica about the innovative partnership between Curtin University and Australian Red Cross Lifeblood. 

Dr. Al-Salami highlighted the significance of this collaboration, this partnership presents an exciting opportunity to combine our research excellence and transforms people’s lives.

Donate to 3ZZZ to diversify the media: https://www.3zzz.com.au//donate/

See omnystudio.com/listener for privacy information.